静脉铁剂与口服铁剂在血液透析贫血患者临床治疗中的应用价值

Application value of intravenous iron and oral iron in the clinical treatment of hemodialysis anemia

目的探讨静脉铁剂与口服铁剂在血液透析(HD)贫血患者临床治疗中的应用价值。方法选取2018年1月~2019年5月我院收治的125例HD贫血患者作为研究对象,按照随机数字表法将其分为静脉组(n=62)和口服组(n=63)。口服组给予多糖铁复合物胶囊治疗,静脉组给予蔗糖铁注射液治疗,比较两组治疗前、后血红蛋白(Hb)、血清铁蛋白(SF)水平,临床治疗效果及不良反应总发生率。结果治疗后静脉组Hb、SF水平高于口服组,差异均有统计学意义(P<0.05)。静脉组治疗总有效率为95.16%,高于口服组的80.95%,差异有统计学意义(P<0.05)。静脉组治疗期并发症总发生率为4.84%,低于对照组的17.46%,差异有统计学意义(P<0.05)。结论在HD贫血患者的治疗采取静脉铁剂治疗,可在疗程内有效提升患者Hb、SF水平水平,提高患者临床治疗效果,减少并发症的发生,效果理想。

Objective To explore the application value of intravenous iron and oral iron in the clinical treatment of hemodialysis(HD) anemia. Methods A total of 125 patients with HD anemia admitted to our hospital from January2018 to May 2019 were selected as the study objects. They were divided into vein group(n=62) and oral group(n=63)according to the random number table method. The oral group was treated with Polysaccharide Iron Complex Capsules,the vein group was treated with Sucrose Iron injection. The levels of hemoglobin(Hb), serum ferritin(SF) before and after treatment were compared between the two groups. Results After treatment, the levels of Hb and SF in venous group were higher than those in oral group, the differences were statistically significant(P<0.05). The total effective rate of vein group was 95.16%, which was higher than that of oral group(80.95%), the difference was statistically significant(P<0.05). The incidence of complications in vein group was 4.84%, which was lower than that in control group(17.46%), the difference was statistically significant(P<0.05). Conclusion In the treatment of HD anemia related patients, intravenous iron treatment can effectively improve the level of Hb and SF in the course of treatment, improve the clinical treatment effect of patients, reduce the incidence of complications, and the effect is ideal.